Skip NavigationSkip to Content

Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope

  1. Author:
    Darbha, R.
    Phogat, S.
    Labrijn, A. F.
    Shu, Y.
    Gu, Y. J.
    Andrykovitch, M.
    Zhang, M. Y.
    Pantophlet, R.
    Martin, L.
    Vita, C.
    Burton, D. R.
    Dimitrov, D. S.
    Ji, X. H.
  2. Author Address

    Dimitrov, DS, NCI Frederick, Macromol Crystallog Lab, POB B, Ft Detrick, MD 21702 USA NCI Frederick, Macromol Crystallog Lab, Ft Detrick, MD 21702 USA. NCI Frederick, Lab Expt & Computat Biol, Ft Detrick, MD 21702 USA. Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA. Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. CEA Saclay, Protein Engn & Res Dept, F-91191 Gif Sur Yvette, France.
    1. Year: 2004
  1. Journal: Biochemistry
    1. 43
    2. 6
    3. Pages: 1410-1417
  2. Type of Article: Article
  1. Abstract:

    The human monoclonal antibody Fab X5 neutralizes a broad range of HIV-1 primary isolates. The crystal structure of X5 has been determined at 1.9 Angstrom resolution. There are two crystallographically independent Fab fragments in the asymmetric unit. The crystallographic R value for the final model is 0.22. The antibody-combining site features a long (22 amino acid residues) CDR H3 with a protruding hook-shaped motif. The X5 structure and site-directed mutagenesis data suggest that X5 amino acid residues W 100 and Y100F in the CDR H3 motif may be critical for the binding of Fab X5 to gp120. X5 bound to a complex of a CD4 mimetic and gp120 with approximately the same kinetics and affinity as to a CD4-gp120 complex, suggesting that specific interactions between CD4 and X5 are unlikely to contribute to the binding of X5 to gp120-CD4 complexes. Binding of X5 to alanine scanning mutants of gp120JR-CSF complexed with CD4 suggested a critical role of the highly conserved amino acid residues at positions 423 and 432. The X5 structure and fine mapping of its epitope may assist in the elucidation of the mechanisms of viral entry and neutralization, and the development of HIV-1 inhibitors and vaccines

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel